Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NasoVAX for Early COVID-19
NCT04442230Phase 2Terminated
- Sponsor
- Altimmune, Inc.
- Start
- Oct 2020
- Primary completion
- Feb 2021
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing NasoVAX with Placebo (2 arms). Primary endpoint: Percentage of Patients With Clinical Worsening. Started Oct 2020; status: terminated.
02
Drugs
nasovax
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04442230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04442230.